TriangleOsimertinib (NCT04410796)
Osimertinib trial for Metastatic Non-small Cell Lung Cancer (NCT04410796). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults starting osimertinib for metastatic non-small-cell lung cancer with an activating EGFR mutation, without prior chemotherapy for metastatic disease. Only patients with persistent EGFR-mutant blood DNA after treatment enter randomization.
The idea: osimertinib blocks mutant EGFR growth signals. Participants continue 80 milligrams orally daily, either alone or with intravenous carboplatin and pemetrexed. Four chemotherapy cycles are followed by pemetrexed maintenance. Researchers compare time without cancer progression. Chemotherapy requires stable or responding disease.
This phase 2 study plans 571 patients. Memorial Sloan Kettering sponsors it; 15 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.